Intended for healthcare professionals


NICE approves combination antibody for advanced melanoma

BMJ 2024; 384 doi: (Published 10 January 2024) Cite this as: BMJ 2024;384:q51
  1. Elisabeth Mahase
  1. The BMJ

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending nivolumab-relatlimab (Opdualag) for people aged 12 or older with untreated advanced melanoma, making nearly 1300 patients eligible for the treatment.1

The combination of two monoclonal antibodies is given …

View Full Text

Log in

Log in through your institution


* For online subscription